TY  - JOUR
AU  - Koerber, Stefan A
AU  - Will, Leon
AU  - Kratochwil, Clemens
AU  - Haefner, Matthias F
AU  - Rathke, Henrik
AU  - Kremer, Christophe
AU  - Merkle, Jonas
AU  - Herfarth, Klaus
AU  - Kopka, Klaus
AU  - Choyke, Peter L
AU  - Holland-Letz, Tim
AU  - Haberkorn, Uwe
AU  - Debus, Juergen
AU  - Giesel, Frederik
TI  - 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.
JO  - Journal of nuclear medicine
VL  - 60
IS  - 2
SN  - 2159-662X
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2018-01906
SP  - 234-240
PY  - 2019
N1  - vol. 60 no. 2 234-240
AB  - The present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy. Changes in TNM classification of malignant tumors (TNM) stage and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared to results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5
LB  - PUB:(DE-HGF)16
C6  - pmid:29976697
DO  - DOI:10.2967/jnumed.118.211086
UR  - https://inrepo02.dkfz.de/record/141400
ER  -